WO2024028744A1 - Traitement de l'anémie aplasique (aa) - Google Patents

Traitement de l'anémie aplasique (aa) Download PDF

Info

Publication number
WO2024028744A1
WO2024028744A1 PCT/IB2023/057752 IB2023057752W WO2024028744A1 WO 2024028744 A1 WO2024028744 A1 WO 2024028744A1 IB 2023057752 W IB2023057752 W IB 2023057752W WO 2024028744 A1 WO2024028744 A1 WO 2024028744A1
Authority
WO
WIPO (PCT)
Prior art keywords
subject
pharmaceutically acceptable
acceptable salts
formula
amount
Prior art date
Application number
PCT/IB2023/057752
Other languages
English (en)
Inventor
Mukul Jain
Amit JOHARAPURKAR
Hardikkumar SAVSANI
Original Assignee
Zydus Lifesciences Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zydus Lifesciences Limited filed Critical Zydus Lifesciences Limited
Publication of WO2024028744A1 publication Critical patent/WO2024028744A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4152—1,2-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A61K31/515—Barbituric acids; Derivatives thereof, e.g. sodium pentobarbital
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Definitions

  • the present invention describes a combination of a suitable prolyl hydroxylase inhibitors with a suitable thrombopoietin (TPO) receptor agonist for the treatment of Aplastic anemia (AA).
  • TPO thrombopoietin
  • the invention also describes the preparation of such combination and its compositions.
  • Aplastic anemia is a rare disorder characterized by suppression of bone marrow function resulting in progressive pancytopenia. 1 The most common cause of AA is immune system attacking the stem cells in bone marrow. Radiation and chemotherapy treatments are the other factors that can injure bone marrow and affect blood cell production. It is diagnosed with values have to lower than 10 g/dl for hemoglobin, 1.5 x 10 9 /L for neutrophils and 50 x 10 9 /L for a platelets. Megakaryocytes pattern may be useful in distinguishing myelodysplasia (MDS) from AA since they are often reduced/absent in AA whereas small or aberrant megakaryocytes are more typical of MDS.
  • MDS myelodysplasia
  • thrombopoietin mimetic TPO agonist
  • TPO thrombopoietin receptor agonist
  • c-Mpl thrombopoietin receptor agonist
  • 6 thrombopoietin (TPO) receptor agonist are intravenous peptibody Romiplostim, oral small molecules y
  • Eltrombopag bisethanolamine chemical name 3'-(2-(l-(3,4-dimethylphenyl)-3-methyl-5-oxo- 1 ,5-dihydro-4H-pyrazol-4-ylidene)hydrazineyl)-2'-hydroxy-[l, l'-biphenyl]-3-carboxylic acid 2- hydroxy-N,N,N-trimethylethan-l-aminium (1: 1).
  • Eltrombopag is a small-molecule, non-peptide thrombopoietin (TPO) receptor agonist that has been shown to stimulate the proliferation and differentiation of megakaryocytes, the bone marrow cells that give rise to blood platelets in pre-clinical research and clinical trials.
  • TPO non-peptide thrombopoietin
  • Eltrombopag bisethanolamine is the active ingredient of the marketed drug Promacta® (US) or Revolade® (EU) indicated in the treatment of chronic immune thrombocytopenia (CIT) in patients who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy. It is also indicated for thrombocytopenia in patients with chronic hepatitis C and in severe aplastic anaemia.
  • Eltrombopag is disclosed in US Patent No. 7,160,870.
  • Eltrombopag bisethanolamine salt is disclosed in US Patent No. 7,547,719.
  • Eltrombopag tromethamine salt is disclosed in International Patent Publication No. W020170042839. Crystalline forms of Eltrombopag choline are disclosed in International Patent Publication No. W020190071111 and US Patent No. 11,072,586.
  • Romiplostim is an active ingredient of the marketed drug Nplate. It is a thrombopoietin receptor agonist indicated for the treatment of thrombocytopenia in patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy. Romiplostim disclosed in US Patent No. 9,145,450 and W02000/24770.
  • the small molecule hypoxia-inducible factor stabilizer compound Desidustat (compound of formula (la)), inhibits the prolyl hydroxylase and has demonstrated hematinic potential by combined effects on endogenous erythropoietin release and efficient iron utilization. It also o enhances erythroid maturation by suppressing hepcidin-ferroportin axis.
  • W02004108681 and W02008002576 covers the prolyl hydroxylase inhibitors named Roxadustat and Vadadustat respectively.
  • W02014102818 discloses compounds of the following general formula
  • formula (la) and its pharmaceutically acceptable salts are effective in the treatment of aplastic anemia when combine with a suitable TPO receptor agonist improve two lineage of hematopoietic precursor cells for the benefit of patients. Also, such combination with cyclosporine will be useful.
  • Embodiments of the invention describes a combination of a suitable prolyl hydroxylase inhibitor or its pharmaceutically acceptable salts and a suitable thrombopoietin (TPO) receptor agonist.
  • TPO thrombopoietin
  • the present invention describes a combination of the compound of formula (la) or its pharmaceutically acceptable salts and a suitable thrombopoietin (TPO) receptor agonist.
  • the present invention provides a combination of the compound of formula (la) or its pharmaceutically acceptable salts and a suitable thrombopoietin (TPO) receptor agonist for the treatment of Aplastic anemia (AA).
  • TPO thrombopoietin
  • a pharmaceutical composition comprising, the compound of formula (la) or its pharmaceutically acceptable salts and a suitable thrombopoietin (TPO) receptor agonist along with at least one a suitable pharmaceutically acceptable carrier, diluents, vehicle or excipient for the treatment of Aplastic anemia (AA).
  • AA Aplastic anemia
  • present invention provides use of combination of the compound of formula (la) or its pharmaceutically acceptable salts and a suitable thrombopoietin (TPO) receptor agonist for the treatment of Aplastic anemia (AA).
  • TPO thrombopoietin
  • the present invention provides a method of treating Aplastic anemia (AA) using the compound of formula (la) or its pharmaceutically acceptable salts.
  • the present invention provides a combination of the compound of formula (la) or its pharmaceutically acceptable salts and a suitable thrombopoietin (TPO) receptor agonist optionally with cyclosporine.
  • TPO thrombopoietin
  • Figure 1 The effect of formula (la), Romiplostim and their combination on white blood cells (A) and Platelets (B) in busulphan-induced aplastic anemia in Balb/c mice.
  • Figure 2 The effect of formula (la) and their combination with Romiplostim on white blood cells (A) and Platelets (B) in cyclophosphamide-induced aplastic anemia in C57 mice.
  • the present invention describes a combination of a suitable prolyl hydroxylase inhibitors with a suitable thrombopoietin (TPO) receptor agonist for the treatment of Aplastic anemia (AA).
  • TPO thrombopoietin
  • the invention also describes the preparation of such combination and its compositions.
  • treatment refers to slowing, stopping, or delaying the progression of the disease or clinical symptoms in a patient, as evidenced by a decrease or elimination of a clinical or diagnostic symptom of the disease, disorder or condition.
  • subject refer to a human and animal.
  • effective amount in the context of the administration of the amount of the drug substance sufficient to have the desired effect.
  • pharmaceutically acceptable use embraces both human and veterinary use.
  • the compound of formula (la) is Desidustat. Combination of a suitable prolyl hydroxylase inhibitors with a suitable thrombopoietin (TPO) receptor agonist
  • the present invention describes a combination of a suitable prolyl hydroxylase inhibitors and suitable thrombopoietin (TPO) receptor agonist.
  • a suitable prolyl hydroxylase inhibitor is selected from Roxadustat, Vadadustat, Daprodustat, Molidustat, Enardustat and the compound of formula (la) or its pharmaceutically acceptable salts.
  • a suitable thrombopoietin (TPO) receptor agonist is Romiplostim or its pharmaceutically acceptable salts, Eltrombopag or its pharmaceutically acceptable salts, Avatrombopag or its pharmaceutically acceptable salts and Lusutrombopag or its pharmaceutically acceptable salts.
  • present invention provides a combination of compound of formula (la) or its pharmaceutically acceptable salts with a suitable thrombopoietin (TPO) receptor agonist, wherein formula (la) is represented by:
  • the pharmaceutical acceptable salts of the compound of formula (la) may be selected from suitable inorganic metal salts or organic amines salts.
  • the inorganic metal salt may be selected from calcium, sodium, potassium, lithium, barium, strontium, magnesium, cesium, copper, cobalt, iron, manganese, lead, aluminum, cadmium, silver, zinc, ammonium and the like.
  • Organic amines salt is selected from methylamine, dimethylamine, ethylamine, diethyl amine, n- propyl amine, isopropyl amine, diisopropyl amine, N-methyl isopropyl amine, n-butyl amine, t- butyl amine, 2-butamine, 1,2-ethane diamine, N-methylglucamine, N,N,N-trimethyl ethanolamine hydroxide (choline), tromethamine, cyclohexylamine, N-methyl cyclohexylamine, guanidine, N-(4-aminobutyl) guanidine, dicyclohexylamine, benzene-methanamine,
  • a suitable thrombopoietin (TPO) receptor agonist is Romiplostim or its pharmaceutically acceptable salts, Eltrombopag or its pharmaceutically acceptable salts, Avatrombopag or its pharmaceutically acceptable salts and Lusutrombopag or its pharmaceutically acceptable salts.
  • Combination as described above can be administered as oral, rectal, topical, nasal, pulmonary, ocular, intestinals or parenteral.
  • an effective amount, e.g., dose, of combination compound or drug can readily be determined by routine experimentation, as can an effective and convenient route of administration and an appropriate formulation.
  • Various formulations and drug delivery systems are available in the art. (See, e.g., Gennaro, ed. (2000) Remington's Pharmaceutical Sciences,; and Hardman, Limbird, and Gilman, eds. (2001) The Pharmacological Basis of Therapeutics, supra.)
  • a suitable routes of administration may, for example, include oral, rectal, topical, nasal, pulmonary, ocular, intestinal, and parenteral administration.
  • Primary routes for parenteral administration include intravenous, intramuscular, and subcutaneous administration.
  • Secondary routes of administration include intraperitoneal, intra-arterial, intra-articular, intracardiac, intracisternal, intradermal, intralesional, intraocular, intrapleural, intrathecal, intrauterine, and intraventricular administration.
  • the indication to be treated, along with the physical, chemical, and biological properties of the drug, dictate the type of formulation and the route of administration to be used, as well as whether local or systemic delivery would be preferred.
  • the compound of formula (la) or its pharmaceutically acceptable salts for oral administration to a subject at a dose in the range of 1 mg to 500 mg or in the range of 50 mg to 450 mg or in the range of 100 mg to 400 mg or in the range of 150 mg to 350 mg or in the range of 200 mg to 300 mg or in the range of 1 mg to 50 mg or in the range of 1 mg to 25 mg to the subject.
  • the compound of formula (la) or a pharmaceutically acceptable salts for oral administration to a subject to provide the compound of formula (la) or a pharmaceutically acceptable salts at a dose of 1 mg to 150 mg.
  • the compound of formula (la) or its pharmaceutically acceptable salts for oral administration to a subject at a dose in the range of 1 mg to 2.5 mg or 2.5 mg to 5 mg or 5 mg to 7.5 mg or 7.5 mg to 10 mg or 10 mg to 12.5 mg or 12.5 mg to 15 mg or 15 mg to 17.5 mg or 17.5 mg to 20 mg or 20 mg to 22.5 mg or 22.5 mg to 25 mg or 25 mg to 30 mg or 30 mg to 35 mg or 35 mg to 40 mg or
  • Eltrombopag is administered orally to a subject in an amount of about 1 mg to about 500 mg.
  • Avatrombopag is administered orally to a subject in an amount of about 1 mg to 100 mg.
  • Lusutrombopag is administered orally to a subject in an amount of about 1 mg to 100 mg.
  • Eltrombopag is administered orally to a subject in an amount of about 12.5 mg, 25 mg, 50 mg, 75 mg and 100 mg.
  • Avatrombopag is administered orally to a subject in an amount of about 20 mg.
  • Lusutrombopag is administered orally to a subject in an amount of about 3 mg.
  • the compound of formula (la) or its pharmaceutically acceptable salts for parenteral administration to a subject at a dose in the range of 1 mg to 2.5 mg or 2.5 mg to 5 mg or 5 mg to 7.5 mg or 7.5 mg to 10 mg or 10 mg to 12.5 mg or 12.5 mg to 15 mg or 15 mg to 17.5 mg or 17.5 mg to 20 mg or 20 mg to 22.5 mg or 22.5 mg to 25 mg or 27.5 mg to 30 mg or 30 mg to 32.5 mg or 32.5 mg to 35 mg or 35 mg to 37.5 mg or 37.5 mg to 40 mg or 40 mg to 42.5 mg or 42.5 mg to 45 mg or 45 mg to 47.5 mg or 47.5 mg to 50 mg.
  • Romiplostim is administered parenterally to a subject in an amount of about 1 pg to about 500 pg, about 50 pg to about 450 pg, about 100 pg to about 400 pg, about 150 pg to about 350 pg, about 200 pg to about 300 pg.
  • Romiplostim is administered parenterally to a subject in an amount of about 125 pg, 250 pg and 500 pg. In a further embodiment.
  • combination of compounds of formula (la) or its pharmaceutically acceptable salts and a suitable thrombopoietin (TPO) receptor agonist can be further characterized according to the dose of compound administered to a subject, where subject is animal or human.
  • compounds of formula (la) or its pharmaceutically acceptable salts and the a suitable thrombopoietin (TPO) receptor agonist are administered as one composition. In some embodiments, compounds of formula (la) or its pharmaceutically acceptable salts and a suitable thrombopoietin (TPO) receptor agonist are administered separately. In some embodiments, compounds of formula (la) or its pharmaceutically acceptable salts and a suitable thrombopoietin (TPO) receptor agonist are administered consecutively. In some embodiments, compounds of formula (la) or its pharmaceutically acceptable salts and the a suitable thrombopoietin (TPO) receptor agonist are administered simultaneously. Method of treating Aplastic anemia (AA) in combination of compound of formula (la) or its pharmaceutically acceptable salts with a suitable thrombopoietin (TPO) receptor agonist
  • the present invention provides a method of treating Aplastic anemia (AA) in a subject, comprising administering a combination of compound of formula (la) or its pharmaceutically acceptable salts with a suitable thrombopoietin (TPO) receptor agonist.
  • AA Aplastic anemia
  • TPO thrombopoietin
  • the pharmaceutical acceptable salts of the compound of formula (la) may be selected from a suitable inorganic metal salts or organic amines salts.
  • the inorganic metal salt may be selected from calcium, sodium, potassium, lithium, barium, strontium, magnesium, cesium, copper, cobalt, iron, manganese, lead, aluminum, cadmium, silver, zinc, ammonium and the like.
  • Organic amines salt is selected from methylamine, dimethylamine, ethylamine, diethyl amine, n- propyl amine, isopropyl amine, diisopropyl amine, N-methyl isopropyl amine, n-butyl amine, t- butyl amine, 2-butamine, 1,2-ethane diamine, N-methylglucamine, N,N,N-trimethyl ethanolamine hydroxide (choline), tromethamine, cyclohexylamine, N-methyl cyclohexylamine, guanidine, N-(4-aminobutyl) guanidine, dicyclohexylamine, benzene-methanamine, ethanolamine, diethanolamine, tris-(hydroxymethyl)methylamine, hydroxylamine, methanaminium, benzylamine, N-methylbenzylamine, N-ethyl benzylamine, 4- methoxybenzylamine,
  • a suitable thrombopoietin (TPO) receptor agonist is Romiplostim or its pharmaceutically acceptable salts, Eltrombopag or its pharmaceutically acceptable salts, Avatrombopag or its pharmaceutically acceptable salts and Lusutrombopag or its pharmaceutically acceptable salts.
  • Combination as described above can be administered as oral, rectal, topical, nasal, pulmonary, ocular, intestinal or parenteral.
  • the compound of formula (la) or its pharmaceutically acceptable salts for oral administration to a subject at a dose in the range of 1 mg to 500 mg or in the range of 50 mg to 450 mg or in the range of 100 mg to 400 mg or in the range of 150 mg to 350 mg or in the range of 200 mg to 300 mg or in the range of 1 mg to 50 mg or in the range of 1 mg to 25 mg to the subject.
  • the compound of formula (la) or a pharmaceutically acceptable salts for oral administration to a subject to provide the compound of formula (la) or a pharmaceutically acceptable salts at a dose of 1 mg to 150 mg.
  • the compound of formula (la) or its pharmaceutically acceptable salts for oral administration to a subject at a dose in the range of 1 mg to 2.5 mg or 2.5 mg to 5 mg or 5 mg to 7.5 mg or 7.5 mg to 10 mg or 10 mg to 12.5 mg or 12.5 mg to 15 mg or 15 mg to 17.5 mg or 17.5 mg to 20 mg or 20 mg to 22.5 mg or 22.5 mg to 25 mg or 25 mg to 30 mg or 30 mg to 35 mg or 35 mg to 40 mg or 40 mg to 45 mg or 45 mg to 50 mg or 50 mg to 55 mg or 55 mg to 60 mg or 60 mg to 65 mg or 65 mg to 70 mg or 70 mg to 75 mg or 75 mg to 80 mg or 80 mg to 85 mg or 85 mg to 90 mg or 90 mg to 95 mg or 95 mg to 100 mg.
  • Eltrombopag is administered orally to a subject in an amount of about 1 mg to about 500 mg.
  • Avatrombopag is administered orally to a subject in an amount of about 1 mg to 100 mg.
  • Lusutrombopag is administered orally to a subject in an amount of about 1 mg to 100 mg.
  • Eltrombopag is administered orally to a subject in an amount of about 12.5 mg, 25 mg, 50 mg, 75 mg and 100 mg.
  • Avatrombopag is administered orally to a subject in an amount of about 20 mg.
  • Lusutrombopag is administered orally to a subject in an amount of about 3 mg.
  • Romiplostim is administered parenterally to a subject in an amount of about 1 pg to about 500 pg, about 50 pg to about 450 pg, about 100 pg to about 400 pg, about 150 pg to about 350 pg, about 200 pg to about 300 pg.
  • Romiplostim is administered parenterally to a subject in an amount of about 125 pg, 250 pg and 500 pg. In a further embodiment.
  • combination of compounds of formula (la) or its pharmaceutically acceptable salts and a suitable thrombopoietin (TPO) receptor agonist can be further characterized according to the dose of compound administered to a subject, where subject is animal or human.
  • compounds of formula (la) or its pharmaceutically acceptable salts and the a suitable thrombopoietin (TPO) receptor agonist are administered as one composition. In some embodiments, compounds of formula (la) or its pharmaceutically acceptable salts and a suitable thrombopoietin (TPO) receptor agonist are administered separately. In some embodiments, compounds of formula (la) or its pharmaceutically acceptable salts and a suitable thrombopoietin (TPO) receptor agonist are administered consecutively. In some embodiments, compounds of formula (la) or its pharmaceutically acceptable salts and the a suitable thrombopoietin (TPO) receptor agonist are administered simultaneously. Pharmaceutical composition of compound of formula (la) or its pharmaceutically acceptable salts and a suitable thrombopoietin (TPO) receptor agonist for use in treating Aplastic anemia (AA)
  • present invention provides a pharmaceutical composition
  • a pharmaceutical composition comprising compound of formula (la) or its pharmaceutically acceptable salts and a suitable thrombopoietin (TPO) receptor agonist optionally with one or more pharmaceutically acceptable excipients for use in treating Aplastic anemia (AA).
  • TPO thrombopoietin
  • the pharmaceutical acceptable salts of the compound of formula (la) may be selected from suitable inorganic metal salts or organic amines salts.
  • the inorganic metal salt may be selected from calcium, sodium, potassium, lithium, barium, strontium, magnesium, cesium, copper, cobalt, iron, manganese, lead, aluminum, cadmium, silver, zinc, ammonium and the like.
  • Organic amines salt is selected from methylamine, dimethylamine, ethylamine, diethyl amine, n- propyl amine, isopropyl amine, diisopropyl amine, N-methyl isopropyl amine, n-butyl amine, t- butyl amine, 2-butamine, 1,2-ethane diamine, N-methylglucamine, N,N,N-trimethyl ethanolamine hydroxide (choline), tromethamine, cyclohexylamine, N-methyl cyclohexylamine, guanidine, N-(4-aminobutyl) guanidine, dicyclohexylamine, benzene-methanamine, ethanolamine, diethanolamine, tris-(hydroxymethyl)methylamine, hydroxylamine, methanaminium, benzylamine, N-methylbenzylamine, N-ethyl benzylamine, 4- methoxybenzylamine,
  • a suitable thrombopoietin (TPO) receptor agonist is Romiplostim or its pharmaceutically acceptable salts, Eltrombopag or its pharmaceutically acceptable salts, Avatrombopag or its pharmaceutically acceptable salts and Lusutrombopag or its pharmaceutically acceptable salts.
  • the pharmaceutical composition as mentioned in above embodiment may be in form of oral, rectal, topical, nasal, pulmonary, ocular, intestinal, or parenteral.
  • the pharmaceutical composition is in the oral form.
  • compositions as described above or anywhere in the specification may be in the form of tablet, capsule and oral liquids.
  • the pharmaceutically acceptable excipients are selected at least one from diluent, binders, disintegrating agents, lubricating agents, glidant agent, sweetener, pH modifier, suspending agent or viscosity modifying agent, flavouring agent and optionally coating redimix.
  • Diluents include, but are not limited to lactose monohydrate, lactose, microcrystalline cellulose, polymethacrylates selected from Eudragit, potassium chloride, sulfobutylether b-cyclodextrin, sodium chloride, spray dried lactose, and preferably sulfobutyl ether b-cyclodextrin combinations thereof and other such materials known to those of ordinary skill in the art.
  • Binders include, but are not limited to hypromellose 3 Cps, carbomers selected from carbopol, gellan, gum Arabic, hydrogenated vegetable oil, polymethacrylates selected from Eudragit, xanthan, lactose and Zein combinations thereof and other such materials known to those of ordinary skill in the art.
  • Disintegrating agents include, but are not limited to, croscarmellose Sodium, bicarbonate salt, chitin, gellan gum, polacrillin potassium and docusate Sodium combinations thereof and other such materials known to those of ordinary skill in the art.
  • Glidant agents include, but are not limited to, colloidal silica, calcium silicate, magnesium silicate, silicon hydrogel, cornstarch, talc, combinations thereof and other such materials known to those of ordinary skill in the art.
  • Lubricant agents include, but are not limited to, calcium stearate, magnesium stearate, mineral oil, stearic acid, zinc stearate, glycerin behenate, hydrogenated vegetable oil, sodium stearyl fumarate and myristic Acid suitable combinations thereof and other such materials known to those of ordinary skill in the art.
  • a suitable pH modifying agents which maintain the pH of the formulation according to the present invention include, but are not limited to Citric acid and other similar excipients and their suitable combinations and other materials known to those of ordinary skill in the art.
  • Suspending agents or viscosity agent according to the present invention include, but are not limited to microcrystalline cellulose and carboxymethylcellulose sodium (Avicel CL 611) and other similar excipients and their suitable combinations and other materials known to those of ordinary skill in the art.
  • Sweetener is selected from Sucrose and all such materials known to those of ordinary skill in the art.
  • Flavouring agent is selected from cherry flavour, orange flavour, mango flavour and all such fruit flavour known to those of ordinary skill in the art.
  • Coating redimix is selected from Opadry Pink all such materials known to those of ordinary skill in the art.
  • the compound of formula (la) or its pharmaceutically acceptable salts for oral administration to a subject at a dose in the range of 1 mg to 500 mg or in the range of 50 mg to 450 mg or in the range of 100 mg to 400 mg or in the range of 150 mg to 350 mg or in the range of 200 mg to 300 mg or in the range of 1 mg to 50 mg or in the range of 1 mg to 25 mg to the subject.
  • the compound of formula (la) or a pharmaceutically acceptable salts for oral administration to a subject to provide the compound of formula (la) or a pharmaceutically acceptable salts at a dose of 1 mg to 150 mg.
  • the compound of formula (la) or its pharmaceutically acceptable salts for oral administration to a subject at a dose in the range of 1 mg to 2.5 mg or 2.5 mg to 5 mg or 5 mg to 7.5 mg or 7.5 mg to 10 mg or 10 mg to 12.5 mg or 12.5 mg to 15 mg or 15 mg to 17.5 mg or 17.5 mg to 20 mg or 20 mg to 22.5 mg or 22.5 mg to 25 mg or 25 mg to 30 mg or 30 mg to 35 mg or 35 mg to 40 mg or 40 mg to 45 mg or 45 mg to 50 mg or 50 mg to 55 mg or 55 mg to 60 mg or 60 mg to 65 mg or 65 mg to 70 mg or 70 mg to 75 mg or 75 mg to 80 mg or 80 mg to 85 mg or 85 mg to 90 mg or 90 mg to 95 mg or 95 mg to 100 mg.
  • Table 1 Stable oral pharmaceutical composition of formula (la)
  • TPO thrombopoietin
  • Eltrombopag is administered orally to a subject in an amount of about 1 mg to about 500 mg.
  • Avatrombopag is administered orally to a subject in an amount of about 1 mg to 100 mg.
  • Lusutrombopag is administered orally to a subject in an amount of about 1 mg to 100 mg.
  • Eltrombopag is administered orally to a subject in an amount of about 12.5 mg, 25 mg, 50 mg, 75 mg and 100 mg.
  • Avatrombopag is administered orally to a subject in an amount of about 20 mg.
  • Lusutrombopag is administered orally to a subject in an amount of about 3 mg.
  • compounds of formula (la) or its pharmaceutically acceptable salts can be further characterized according to the dose of compound administered to a subject, where subject is animal or human.
  • compounds of formula (la) or its pharmaceutically acceptable salts and a suitable thrombopoietin (TPO) receptor agonist are administered as one composition.
  • compounds of formula (la) or its pharmaceutically acceptable salts and a suitable thrombopoietin (TPO) receptor agonist are administered separately.
  • compounds of formula (la) or its pharmaceutically acceptable salts and a suitable thrombopoietin (TPO) receptor agonist are administered consecutively.
  • compounds of formula (la) or its pharmaceutically acceptable salts and the a suitable thrombopoietin (TPO) receptor agonist are administered simultaneously.
  • composition of combination of compound of formula (la) or its pharmaceutically acceptable salts and Romiplostim is in parenteral form.
  • composition of combination of compound of formula (la) or its pharmaceutically acceptable salts and Romiplostim can be administered via parenteral rout.
  • parenteral formulation of compound of formula (la) or its pharmaceutically acceptable salts can be prepared as method known in art.
  • AA Aplastic anemia
  • the pharmaceutically acceptable excipients are selected at least one from dextrose in water, captisol in water, microemulsion and cosolvent or emulsifying agent with pH adjustment for use in treating Aplastic anemia (AA).
  • Cosolvent or emulsifying agent is selected from CaptexTM 300, SolutolTM Hl 5, Propylene glycol, PhospholiponTM 90G, SolutolTM HS15, dimethylacetamide with ethanol, PEG400 and N- methylpyrrolidone.
  • TPO thrombopoietin
  • AA Aplastic anemia
  • the pharmaceutical composition as described above is in parenteral form.
  • a suitable thrombopoietin (TPO) receptor agonist is Romiplostim or its pharmaceutically acceptable salts.
  • the pharmaceutically acceptable excipients are selected at least one from a buffer, a bulking agent, a stabilizing agent and a surfactant for the treatment of Aplastic Anemia (AA).
  • AA Aplastic Anemia
  • Buffer is selected from glycine, histidine, glutamate, succinate, phosphate, acetate and aspartate.
  • Bulking agent is selected from mannitol, glycine, sucrose, dextran, polyvinylpyrolidone, carboxymethylcellulose, lactose, sorbitol, trehalose or xylitol.
  • the stabilizing agent is selected from sucrose, trehalose, mannose, maltose, lactose, glucose, raffinose, cellobiose, gentiobiose, isomaltose, arabinose, glucosamine, fructose, mannitol, sorbitol, glycine, arginine HCL, poly-hydroxy compounds, including polysaccharides such as dextran, starch, hydroxyethyl starch, cyclodextrins, N-methylpyrollidene, cellulose and hyaluronic acid, sodium chloride.
  • the surfactant is selected from sodium lauryl sulfate, dioctyl sodium sulfosuccinate, dioctyl sodium sulfonate, chenodeoxycholic acid, N-lauroylsarcosine sodium salt, lithium dodecyl sulfate, 1 -octanesulfonic acid sodium salt, sodium cholate hydrate, sodium deoxycholate, glycodeoxycholic acid sodium salt, benzalkonium chloride or benzethonium chloride, cetylpyridinium chloride monohydrate, hexadecyltrimethylammonium bromide, CHAPS, CHAPSO, SB3-10, SB3-12, digitonin, Triton X-100, Triton X-114, lauromacrogol 400, polyoxyl 40 stearate, polyoxyethylene hydrogenated castor oil 10, 40, 50 and 60, glycerol monostearate, polysorbate 20, 40, 60, 65 and 80
  • Romiplostim is administered parenterally to a subject in an amount of about 1 pg to about 500 pg, about 50 pg to about 450 pg, about 100 pg to about 400 pg, about 150 pg to about 350 pg, about 200 pg to about 300 pg.
  • Romiplostim is administered parenterally to a subject in an amount of about 125 pg, 250 pg and 500 pg.
  • compounds of formula (la) or its pharmaceutically acceptable salts can be further characterized according to the dose of compound administered to a subject, where subject is animal or human.
  • compounds of formula (la) or its pharmaceutically acceptable salts and Romiplostim are administered as one composition. In some embodiments, compounds of formula (la) or its pharmaceutically acceptable salts and Romiplostim are administered separately. In some embodiments, compounds of formula (la) or its pharmaceutically acceptable salts and Romiplostim are administered consecutively. In some embodiments, compounds of formula (la) or its pharmaceutically acceptable salts and Romiplostim are administered simultaneously.
  • Parenteral formulation can be administered by Subcutaneous, Intramuscular, Intravenous and Intrathecal.
  • present invention provides use of combination of compound of formula (la) or its pharmaceutically acceptable salts with a suitable thrombopoietin (TPO) receptor agonist for treating Aplastic anemia (AA).
  • the pharmaceutical acceptable salts of the compound of formula (la) may be selected from a suitable inorganic metal salts or organic amines salts.
  • the inorganic metal salt may be selected from calcium, sodium, potassium, lithium, barium, strontium, magnesium, cesium, copper, cobalt, iron, manganese, lead, aluminum, cadmium, silver, zinc, ammonium and the like.
  • Organic amines salt is selected from methylamine, dimethylamine, ethylamine, diethyl amine, n- propyl amine, isopropyl amine, diisopropyl amine, N-methyl isopropyl amine, n-butyl amine, t- butyl amine, 2-butamine, 1,2-ethane diamine, N-methylglucamine, N,N,N-trimethyl ethanolamine hydroxide (choline), tromethamine, cyclohexylamine, N-methyl cyclohexylamine, guanidine, N-(4-aminobutyl) guanidine, dicyclohexylamine, benzene-methanamine, ethanolamine, diethanolamine, tris-(hydroxymethyl)methylamine, hydroxylamine, methanaminium, benzylamine, N-methylbenzylamine, N-ethyl benzylamine, 4- methoxybenzylamine,
  • a suitable thrombopoietin (TPO) receptor agonist is Romiplostim or its pharmaceutically acceptable salts, Eltrombopag or its pharmaceutically acceptable salts, Avatrombopag or its pharmaceutically acceptable salts and Lusutrombopag or its pharmaceutically acceptable salts. Combination as described above can be administered as oral, rectal, topical, nasal, pulmonary, ocular, intestinal, or parenteral.
  • the compound of formula (la) or its pharmaceutically acceptable salts for oral administration to a subject at a dose in the range of 1 mg to 500 mg or in the range of 50 mg to 450 mg or in the range of 100 mg to 400 mg or in the range of 150 mg to 350 mg or in the range of 200 mg to 300 mg or in the range of 1 mg to 50 mg or in the range of 1 mg to 25 mg to the subject.
  • the compound of formula (la) or a pharmaceutically acceptable salts for oral administration to a subject to provide the compound of formula (la) or a pharmaceutically acceptable salts at a dose of 1 mg to 150 mg.
  • the compound of formula (la) or its pharmaceutically acceptable salts for oral administration to a subject at a dose in the range of 1 mg to 2.5 mg or 2.5 mg to 5 mg or 5 mg to 7.5 mg or 7.5 mg to 10 mg or 10 mg to 12.5 mg or 12.5 mg to 15 mg or 15 mg to 17.5 mg or 17.5 mg to 20 mg or 20 mg to 22.5 mg or 22.5 mg to 25 mg or 25 mg to 30 mg or 30 mg to 35 mg or 35 mg to 40 mg or 40 mg to 45 mg or 45 mg to 50 mg or 50 mg to 55 mg or 55 mg to 60 mg or 60 mg to 65 mg or 65 mg to 70 mg or 70 mg to 75 mg or 75 mg to 80 mg or 80 mg to 85 mg or 85 mg to 90 mg or 90 mg to 95 mg or 95 mg to 100 mg.
  • Eltrombopag is administered orally to a subject in an amount of about 1 mg to about 500 mg.
  • Avatrombopag is administered orally to a subject in an amount of about 1 mg to 100 mg.
  • Lusutrombopag is administered orally to a subject in an amount of about 1 mg to 100 mg.
  • Eltrombopag is administered orally to a subject in an amount of about 12.5 mg, 25 mg, 50 mg, 75 mg and 100 mg.
  • Avatrombopag is administered orally to a subject in an amount of about 20 mg.
  • Lusutrombopag is administered orally to a subject in an amount of about 3 mg.
  • Romiplostim is administered parenterally to a subject in an amount of about 1 pg to about 500 pg, about 50 pg to about 450 pg, about 100 pg to about 400 pg, about 150 pg to about 350 pg, about 200 pg to about 300 pg.
  • Romiplostim is administered parenterally to a subject in an amount of about 125 pg, 250 pg and 500 pg. In a further embodiment.
  • combination of compounds of formula (la) or its pharmaceutically acceptable salts and a suitable thrombopoietin (TPO) receptor agonist can be further characterized according to the dose of compound administered to a subject, where subject is animal or human.
  • compounds of formula (la) or its pharmaceutically acceptable salts and the a suitable thrombopoietin (TPO) receptor agonist are administered as one composition. In some embodiments, compounds of formula (la) or its pharmaceutically acceptable salts and a suitable thrombopoietin (TPO) receptor agonist are administered separately. In some embodiments, compounds of formula (la) or its pharmaceutically acceptable salts and a suitable thrombopoietin (TPO) receptor agonist are administered consecutively. In some embodiments, compounds of formula (la) or its pharmaceutically acceptable salts and the a suitable thrombopoietin (TPO) receptor agonist are administered simultaneously.
  • the present invention provides a method of treating Aplastic anemia (AA) in a subject, comprising administering an effective amount of compound of formula (la) or its pharmaceutically acceptable salts.
  • the pharmaceutical acceptable salts of the compound of formula (la) may be selected from a suitable inorganic metal salts or organic amines salts.
  • the inorganic metal salt may be selected from calcium, sodium, potassium, lithium, barium, strontium, magnesium, cesium, copper, cobalt, iron, manganese, lead, aluminum, cadmium, silver, zinc, ammonium and the like.
  • Organic amines salt is selected from methylamine, dimethylamine, ethylamine, diethyl amine, n- propyl amine, isopropyl amine, diisopropyl amine, N-methyl isopropyl amine, n-butyl amine, t- butyl amine, 2-butamine, 1,2-ethane diamine, N-methylglucamine, N,N,N-trimethyl ethanolamine hydroxide (choline), tromethamine, cyclohexylamine, N-methyl cyclohexylamine, guanidine, N-(4-aminobutyl) guanidine, dicyclohexylamine, benzene-methanamine, ethanolamine, diethanolamine, tris-(hydroxymethyl)methylamine, hydroxylamine, methanaminium, benzylamine, N-methylbenzylamine, N-ethyl benzylamine, 4- methoxybenzylamine,
  • the compound of formula (la) or its pharmaceutically acceptable salts for administration to a subject at a dose in the range of 1 mg to 500 mg or in the range of 50 mg to 450 mg or in the range of 100 mg to 400 mg or in the range of 150 mg to 350 mg or in the range of 200 mg to 300 mg or in the range of 1 mg to 50 mg or in the range of 1 mg to 25 mg to the subject.
  • the compound of formula (la) or a pharmaceutically acceptable salts for administration to a subject to provide the compound of formula (la) or a pharmaceutically acceptable salts at a dose of 1 mg to 150 mg.
  • the compound of formula (la) or its pharmaceutically acceptable salts for administration to a subject at a dose in the range of 1 mg to 2.5 mg or 2.5 mg to 5 mg or 5 mg to 7.5 mg or 7.5 mg to 10 mg or 10 mg to 12.5 mg or 12.5 mg to 15 mg or 15 mg to 17.5 mg or 17.5 mg to 20 mg or 20 mg to 22.5 mg or 22.5 mg to 25 mg or 25 mg to 30 mg or 30 mg to 35 mg or 35 mg to 40 mg or 40 mg to 45 mg or 45 mg to 50 mg or 50 mg to 55 mg or 55 mg to 60 mg or 60 mg to 65 mg or 65 mg to 70 mg or 70 mg to 75 mg or 75 mg to 80 mg or 80 mg to 85 mg or 85 mg to 90 mg or 90 mg to 95 mg or 95 mg to 100 mg.
  • compounds of formula (la) or its pharmaceutically acceptable salts can be further characterized according to the dose of compound administered to a subject, where subject is animal or human.
  • composition of formula (la) or its pharmaceutically acceptable salts can be prepared as anywhere disclosed in the specification.
  • a suitable thrombopoietin (TPO) receptor agonist is Eltrombopag or its pharmaceutically acceptable salts, Romiplostim or its pharmaceutically acceptable salts, Avatrombopag or its pharmaceutically acceptable salts and Lusutrombopag or its pharmaceutically acceptable salts.
  • the pharmaceutical acceptable salts of the compound of formula (la) may be selected from a suitable inorganic metal salt or organic amines salts.
  • the inorganic metal salt may be selected from calcium, sodium, potassium, lithium, barium, strontium, magnesium, cesium, copper, cobalt, iron, manganese, lead, aluminum, cadmium, silver, zinc, ammonium and the like.
  • Organic amines salt is selected from methylamine, dimethylamine, ethylamine, diethyl amine, n- propyl amine, isopropyl amine, diisopropyl amine, N-methyl isopropyl amine, n-butyl amine, t- butyl amine, 2-butamine, 1,2-ethane diamine, N-methylglucamine, N,N,N-trimethyl ethanolamine hydroxide (choline), tromethamine, cyclohexylamine, N-methyl cyclohexylamine, guanidine, N-(4-aminobutyl) guanidine, dicyclohexylamine, benzene-methanamine, ethanolamine, diethanolamine, tris-(hydroxymethyl)methylamine, hydroxylamine, methanaminium, benzylamine, N-methylbenzylamine, N-ethyl benzylamine, 4- methoxybenzylamine,
  • present invention provides a pharmaceutical composition
  • a pharmaceutical composition comprising compound of formula (la) or its pharmaceutically acceptable salts and a suitable thrombopoietin (TPO) receptor agonist optionally with cyclosporine.
  • TPO thrombopoietin
  • compositions, dosage form and rout of administration as described above or anywhere in the specification.
  • the compound of formula (la) may be prepared by any of the methods known in the art including those processes disclosed in the prior art such as those mentioned elsewhere in the specification.
  • Romiplostim may be prepared by any of the methods known in the art including those processes disclosed in the prior art such as those mentioned elsewhere in the specification.
  • TPO thrombopoietin
  • Example 1 Effect of formula (la), Romiplostim and its combination on busulphan-induced aplastic anemia in Balb/c mice
  • Aplastic anemia (AA) was induced in BALB/c mice by administration of busulphan (BU).
  • BU was dissolved in acetone at concentrations of 5-10 mg/mL.
  • deionized water was added to the BU-acetone solution and the solution was given by intraperitoneal (ip) injection at dose of 9 mg/kg.
  • Control mice were given vehicle at the same dose volume.
  • 9 Compound of formula (la) (15 mg/kg, PO, daily) and Romiplostim (50 pg/kg, SC, once a week) combination were administered.
  • mice were be dosed with vehicle or BU on 10 occasions over a period of 21 days (days 1, 3, 6, 8, 10, 13, 15, 17, 19 and 21). Between 1 to 127 days after the final BU dose, mice from each group were autopsied for blood. 9
  • Example 2 Effect of formula (la) and its combination with Romiplostim on cyclophosphamide-induced aplastic anemia in C57 mice
  • Aplastic anemia was induced in C57 mice by administration of cyclophosphamide.
  • Cyclophosphamide was dissolved in deionized water at concentrations of 20 mg/mL. Immediately before administration, deionized water was added to the stock solution and the solution was given by intraperitoneal (ip) injection at dose of 100 mg/kg. Mice were dosed with vehicle or cyclophosphamide for 4 days. Control mice were given vehicle at the same dose volume. 10 Compound of formula (la) (15 mg/kg, PO, daily) and Romiplostim (30 pg/kg, SC, once a week) combination were administered.
  • WBC cyclophosphamide-induced aplastic anemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La présente invention concerne une combinaison associant un inhibiteur de prolyl hydroxylase approprié et un agoniste du récepteur de la thrombopoïétine (TPO) approprié pour le traitement de l'anémie aplasique (AA). L'invention concerne également la préparation d'une telle combinaison et des compositions de celle-ci.
PCT/IB2023/057752 2022-08-01 2023-07-31 Traitement de l'anémie aplasique (aa) WO2024028744A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN202221043866 2022-08-01
IN202221043866 2022-08-01

Publications (1)

Publication Number Publication Date
WO2024028744A1 true WO2024028744A1 (fr) 2024-02-08

Family

ID=89848782

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2023/057752 WO2024028744A1 (fr) 2022-08-01 2023-07-31 Traitement de l'anémie aplasique (aa)

Country Status (1)

Country Link
WO (1) WO2024028744A1 (fr)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014102818A1 (fr) * 2012-12-24 2014-07-03 Cadila Healthcare Limited Dérivés inédits de quinolone
WO2020085467A1 (fr) * 2018-10-26 2020-04-30 協和キリン株式会社 Composition pharmaceutique destinée au traitement de l'anémie aplasique
WO2022155352A1 (fr) * 2021-01-13 2022-07-21 Dyve Biosciences, Inc. Formulations d'agents pénétrants transdermiques pour l'administration de médicaments

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014102818A1 (fr) * 2012-12-24 2014-07-03 Cadila Healthcare Limited Dérivés inédits de quinolone
WO2020085467A1 (fr) * 2018-10-26 2020-04-30 協和キリン株式会社 Composition pharmaceutique destinée au traitement de l'anémie aplasique
WO2022155352A1 (fr) * 2021-01-13 2022-07-21 Dyve Biosciences, Inc. Formulations d'agents pénétrants transdermiques pour l'administration de médicaments

Similar Documents

Publication Publication Date Title
US5180721A (en) Combinations of selective alpha-adrenergic agonists and antagonists useful in lowering intraocular pressure
AU2022271435A1 (en) Ophthalmic compositions
CA2029657C (fr) Compositions pharmaceutiques permettant de reduire la tension intra-oculaire et mode d'utilisation
US5281591A (en) Combinations of selective alpha-adrenergic agonists and antagonists useful in lowering intraocular pressure
JP2021519764A (ja) 線維性疾患を処置する方法
US11413260B2 (en) Use of 1,3-propanedisulfonic acid or pharmaceutically acceptable salts thereof for the treatment of sarcoidosis
WO2024028744A1 (fr) Traitement de l'anémie aplasique (aa)
US11666563B2 (en) Pharmaceutical preparation containing pyridyl aminoacetic acid compound
CA2371517C (fr) Un agent ameliore pour l'hypo-albuminemie
JP7062846B1 (ja) 安定な医薬組成物
JP2002114711A (ja) 外用剤組成物
US20030143265A1 (en) Method for treatment of sepsis
JP2003522121A (ja) 多発性硬化症の処置のためのリルゾールの使用
EP3730138B1 (fr) Combinaison de sepetaprost et de ripasudil pour l'utilisation dans la prophylaxie ou le traitement du glaucome ou de l'hypertension oculaire
JP2005047909A (ja) ピペリジン誘導体を有効成分とする掻痒治療剤
JP2016512532A (ja) 硝子体内および前房内経路を通じて眼圧および眼疾患を治療するためのα−２アドレナリン作動薬
JP6963651B2 (ja) エピナスチン又はその塩を含有する水性組成物
JP7118579B1 (ja) エピナスチン又はその塩を含有する水性組成物
JP2012250953A (ja) アデノシン誘導体とα２受容体作動薬の組合せ剤
EP4248970A1 (fr) Compositions ophtalmiques comprenant de la cétirizine et du tocofersolan
EP4282403A2 (fr) Composition ophtalmique
JP5299449B2 (ja) 外用剤組成物
EP3730143A1 (fr) Association de l'omidénépag
KR20220014025A (ko) 나파모스타트 메실레이트와 덱사메타손 또는 그 염을 유효성분으로 포함하는 약학적 조성물
TR201510664A1 (tr) Oti̇k ve/veya oftalmi̇k uygulanan terapöti̇k formülasyonlar

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23849602

Country of ref document: EP

Kind code of ref document: A1

DPE2 Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101)